Optimizing therapy for mild to moderate IBD
In this presentation from the 2018 Mastering Clinical Challenges and Emerging Therapies in IBD conference, Dr. Stephen B. Hanauer discusses best practices for optimizing therapy for mild-to-moderate inflammatory bowel disease (IBD), with a focus on the foundational therapeutic agents, 5-ASA, corticosteroids, and immunomodulators.
Earn CME Credit for a related activity:
https://naccme.com/program/7301
© 2018 Imedex, LLC.
Видео Optimizing therapy for mild to moderate IBD канала ImedexCME
Earn CME Credit for a related activity:
https://naccme.com/program/7301
© 2018 Imedex, LLC.
Видео Optimizing therapy for mild to moderate IBD канала ImedexCME
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Update on vedolizumab in IBD: What have we learned?
When and How to Use Immunomodulators and Biologics in IBD
Living with Ulcerative Colitis
Crohn Disease | Clinical Presentation
Understanding non-response and loss of response in IBD: Which is it and when do we change classes?
Implementing treatment pathways for the management of ulcerative colitis and Crohn's disease
How can we best determine endoscopic severity in ulcerative colitis and Crohn's disease (videos)?
Inflammatory Bowel Disease - Crohns and Ulcerative Colitits
Understanding the Risks and Benefits of IBD Therapies
Evolving Approaches to IBD Management: From Step-Care to Treat-to-Target
PRO: Vedolizumab should be used before anti-TNFs for moderate to severe IBD
IBD: Beyond Combination Therapy
Ulcerative Colitis: A Guide for Patients
New Biologic Therapies that Target the IL-12/23 Pathway
Positioning of Biologics and New Therapeutics for Crohn's Disease
UIcerative Colitis 101
Who should receive early anti-TNF therapy: With what benefits and risks?
Future Therapies in Multiple Myeloma
Treatment of Inpatients with Severe, Refractory Ulcerative Colitis
Migraine Prevention: New Opportunities for Pain Relief